BioTime, Inc. (NYSEMKT:BTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 – Results of Operations and Financial Condition
On March 16, 2017, BioTime, Inc. issued a press release
announcing its financial results for the fourth quarter and
fiscal year ended December 31, 2016. A copy of the press release
is attached as Exhibit 99.1, which, in its entirety, is
incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press release dated March 16, 2017 |
About BioTime, Inc. (NYSEMKT:BTX)
BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location. BioTime, Inc. (NYSEMKT:BTX) Recent Trading Information
BioTime, Inc. (NYSEMKT:BTX) closed its last trading session up +0.02 at 3.10 with 251,086 shares trading hands.